Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 5/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21410772 | 1.00 | BDKRB1 (0.41) | BDKRB1HCRTR2KDRNPC1POLB | |
| SCHEMBL23211395 | 0.91 | HCRTR2 (0.41) | BDKRB1HCRTR2KDRNPC1POLB | |
| SCHEMBL21411198 | 0.91 | HCRTR2 (0.41) | BDKRB1HCRTR2KDRNPC1POLB | |
| SCHEMBL21427619 | 0.84 | HCRTR2 (0.45) | HCRTR2ALDH1A1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL23211369 | 0.83 | HTT (0.40) | HCRTR2SMN1; SMN2L3MBTL1HTT | |
| SCHEMBL23211371 | 0.83 | HTT (0.40) | HCRTR2SMN1; SMN2L3MBTL1HTT | |
| SCHEMBL21410903 | 0.82 | HCRTR2 (0.43) | HCRTR2NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL23211329 | 0.82 | HCRTR2 (0.43) | HCRTR2NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL23211400 | 0.82 | HCRTR2 (0.45) | HCRTR2ALDH1A1HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL21410827 | 0.82 | HCRTR2 (0.45) | HCRTR2ALDH1A1HPGDSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174685-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-30 | — | — | US | disclosed |
| US-11905297-B2 | OX2R compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230122024-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-20 | — | — | US | disclosed |
| US-11479560-B2 | OX2R compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-10-25 | — | — | US | disclosed |
| US-11472813-B2 | OX2R compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-10-18 | — | — | US | disclosed |
| US-20210163494-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210107914-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-04-15 | — | — | US | disclosed |
| CN-112165940-A | OX2R compound | 德克萨斯州立大学董事会 | 2021-01-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479560-B2 | OX2R compounds | HCRTR2, HCRTR1, OXTR | BDKRB1 332/4885HCRTR2 1/4885KDR 2823/4885 |
| US-11905297-B2 | OX2R compounds | HCRTR2, HCRTR1, OXTR | BDKRB1 332/4885HCRTR2 1/4885KDR 2823/4885 |
| US-20240174685-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | BDKRB1 332/4885HCRTR2 1/4885KDR 2823/4885 |
| US-20210107914-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | BDKRB1 332/4885HCRTR2 1/4885KDR 2823/4885 |
| US-20230122024-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | BDKRB1 332/4885HCRTR2 1/4885KDR 2823/4885 |
| US-11472813-B2 | OX2R compounds | HCRTR2, HCRTR1, OXTR | BDKRB1 332/4885HCRTR2 1/4885KDR 2823/4885 |
| US-20210163494-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | BDKRB1 332/4885HCRTR2 1/4885KDR 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.